Market Introduction

The global neurology market was valued at USD 31 billion in 2024 and grew at a CAGR of 9% from 2025 to 2034. The market is expected to reach USD 73.38 billion by 2034. The rising awareness about neurological disorders will drive the growth of the global neurology market.

The medical field dedicated to diagnosing and treating nervous system diseases of brain, spinal cord and peripheral nerves with muscles falls under the discipline of neurology. Medical specialists known as neurologists perform assessments for nervous system disorders while treating these conditions by using clinical evaluations. Neurology deals with multiple disorders among which the main ones are Alzheimer's disease, Parkinson's disease, stroke epilepsy, multiple sclerosis and migraine headaches. Neurologists cooperate with neurosurgeons, psychiatrists and rehabilitation professionals to deliver complete treatment to clients with neurological diseases. Neurology sets out to investigate the complex operations which occur inside the nervous system. Neurologists develop medical interventions that include medications combined with life-style modifications as well as physical therapy and surgery for correct analysis of patients' neurological state. The advancements in neuroscience resulted in the development of deep brain stimulation as a new procedure for specific medical conditions. The advancements in neurology pursue continual progression because new technological developments and research produce better understandings of brain and nervous system operations. The early detection and management of neurological diseases became possible due to newly developed MRI and CT scan technologies.

Get an overview of this study by requesting a free sample

Recent Development

• Early neurological deterioration (END) is frequently a risk for patients with branch atherosclerosis disease (BAD). Argatroban plus dual antiplatelet therapy (DAPT) treatment decreased the incidence of END and improved 90-day functional results in a recently published randomised controlled trial, indicating that the combination of these treatments may be a useful tactic for people with BAD. 111 BAD patients who arrived within 48 hours of the commencement of their symptoms were included in the Chinese-based trial, which was carried out at 4 centres between 2021 and 2023.

Market Dynamics

Drivers

Rising awareness about these conditions and technological advancements in the neuroscience – Neurological diagnostics have improved because medical technology advances brought MRI and PET scans into practice which enhance both detection accuracy and assessment capabilities of neurological disorders. Additionally, minimally invasive surgical techniques have made treatments more precise and effective thus setting forth increased demand for specialized neurological medical treatment. Personalized medicine and neurogenetics in neurology let healthcare providers create specific medical approaches which recognize individual patient genetics therefore delivering better clinical outcomes. The use of artificial intelligence (AI) in neurological diseases diagnostics and management continues to enhance service demand through efficient accurate medical evaluations. The rate of early diagnosis and heightened patient awareness functions independently as essential growth factors. The wider spread of public education about neurological disorders results in patients who recognize symptoms at an early stage and get professional medical care.

Restraints

Treatments of neurological disorders are expensive – The main financial barriers alongside poor healthcare infrastructure act as constraints for the market. The main obstacle in obtaining neurological treatments stems from their high expenses. Patients with neurological disorders need sophisticated exams along with prolonged medicinal treatments combined with surgeries and therapeutic interventions which prove to be costly. The associated costs prove too expensive for numerous people who lack proper insurance coverage and enough savings. Lack of knowledge about neurological conditions along with insufficient education about these disorders reduces the number of patients who seek treatment. The population often misses neurological condition symptoms and they remain unaware about early medical attention benefits. Community assumptions linked to some neurological disorders create obstacles for patients who delay their healthcare access and fail to receive proper medical attention.

Opportunities

The increasing incidence of neurological disorders – The worldwide aging population represents the rising incidence of neurological disordered because older adults have higher susceptibility to neurological dementia and Parkinson's disease and stroke. Life expectancy growth results in increased occurrences of these conditions which fuels the requirement for concentrated neurology medical care. Lifestyle choices that combine stress, unhealthy eating habits and absence of physical activity leads to higher rates of migraines epilepsy and strokes because these health conditions require additional neurology service provision. Improvements in healthcare infrastructure together with specialized medical facilities growth and trained professional availability leads to enhanced accessibility of neurology care in numerous regions. The increased accessibility of treatment enables many new groups of patients to receive care particularly in underdeveloped countries. The increase in health insurance coverage for neurological medical services has simultaneously lowered their costs and improved access thus more patients can receive neurological care.

Segment Analysis

Regional segmentation analysis

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the most significant global neurology market, with a 42% market revenue share in 2024.

One of the most affected regions worldwide concerning neurological conditions exists in the United States where it encounters elevated occurrences of Alzheimer’s disease alongside Parkinson’s disease and epilepsy and these numbers increase given the aging demographic. The expanding base of neurological patients requires a substantial amount of specialized neurology care and diagnostic services and treatment solutions. North American healthcare facilities operate through advanced medical equipment such as MRI scan and PET scan machines and advanced electrophysiological monitoring tools in their medical centres and hospitals. The medical facilities within North America deliver complete neurological care to their patients by providing advanced services from diagnosis through medical treatment to rehabilitation programs to maintain their regional leadership role. The neurological drug development market is advanced by leading pharmaceutical and biotech companies along with their continuous discoveries, innovations and scientific breakthroughs. The region benefits from extensive research independently conducted by governmental institutions and other private entities as well as universities.

Check the geographical analysis of this market by requesting a free sample

• In order to help countries meet the 2031 targets of the Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders (IGAP), WHO released a new implementation toolkit that outlines specific actions and resources for improving services for individuals with neurological disorders. Globally, neurological disorders are the primary cause of illness and disability. In 2022, the Seventy-fifth World Health Assembly unanimously adopted the neurology action plan, which lays out a comprehensive plan to improve services by promoting research and innovation, lowering discrimination, increasing awareness, and fortifying policies, systems, and services.

Type of neurological disorder Segment Analysis

The type of neurological disorder segment is divided into neurodegenerative diseases, cerebrovascular disorders, epileptic disorders, demyelinating diseases, headache disorders, neuromuscular disorders and others. The neurodegenerative diseases segment dominated the market, with a market share of around 38% in 2024. Alzheimer’s disease, the most common form of dementia, and Parkinson’s disease, a progressive movement disorder, represent major public health concerns, with millions of people worldwide affected. An ample market demand exists because consistent medical intervention is needed for managing symptoms and slowing disease progression. Alzheimer's disease treatment requires disease-modifying therapies that medical professionals heavily seek while Parkinson's disease patients mostly require treatments for symptom management including tremor control and motor dysfunction improvement. Neurodegenerative diseases impose substantial financial strain on healthcare systems because they require extensive patient care so pharmaceutical companies along with healthcare providers maintain this segment as their main focus. Future research directions about disease mechanisms and medication development will sustain the prevalence of neurodegenerative diseases across the neurology market. These conditions will drive market expansion because they exist in high numbers and require expensive care for extended periods.

• Imagine a society in which early detection is more common, treatment choices are backed by data-driven insights, and neurological diagnoses are established with increased accuracy.  This is the goal of the Mayo Clinic Neurology Artificial Intelligence Program (NAIP), which is spearheading new research in which AI is used as a potent instrument to complement and enhance medical practitioners' knowledge. The NAIP team is evaluating StateViewer, a platform developed by Mayo that uses artificial intelligence to identify similar brain disease cases in Mayo's dispersed data network based on a patient's PET scan. Researchers believe that by improving diagnostic precision, StateViewer will assist care teams in diagnosing dementia, including frontotemporal dementia, Lewy body dementia, and Alzheimer's disease, and assist in directing patient treatment choices.

Treatment type Segment Analysis

The treatment type segment is divided into pharmaceuticals, surgical treatments, diagnostics, therapies and others. The pharmaceuticals segment dominated the market, with a market share of around 37% in 2024. Medical drugs serve essential purposes in neurology treatment by managing symptoms alongside slowing disease advancement and enhancing patient health conditions. There exist disease-modifying therapies (DMTs) that serve as primary treatment options for Alzheimer’s and Parkinson’s disease because they work to stop or delay the progression of these serious conditions. Medications known as antiepileptic drugs function as the core treatment against seizures in epilepsy while specific drugs including triptans and preventive therapies help manage the widespread condition of migraines. The development of molecular biology along with neurogenetics and biopharmaceuticals has led to new therapeutic drugs that match individual genetic characteristics thus producing enhanced efficiency with reduced adverse effects. Pharmaceutical companies dedicate abundant financial resources to neurology R&D because neurological diseases are increasingly prevalent while healthcare professionals seek imperative new treatment methods. Pharmaceuticals play a critical role in prolonged neurology care because most neurological conditions persist for extended periods thus requiring long-term treatment options for both disease modification and symptom control. Neurology market expansion and innovation will continue under advanced pharmaceutical research and drug delivery system developments.

• The Child Neurology Society (CNS) and Baylor Genetics, a clinical diagnostic laboratory leading the way in genetic testing, announced their partnership as an official 2025–2026 genetic testing partner. With a high diagnostic yield of up to 40–60% and written findings available as soon as five days after patient sample receipt, Baylor Genetics' flagship rapid WGS and WES assays are among the most accurate and quick precision diagnostic techniques on the market.

End user Segment Analysis

The end user segment is divided into hospitals, neurology clinics, ambulatory surgical centers (ASCs), research institutes and others. The hospitals segment dominated the market, with a market share of around 42% in 2024. A hospital offers its patients access to a comprehensive array of diagnosis and treatment solutions at one place. Hospitals offer a complete healthcare atmosphere that allows neurologists neurosurgeons and nurses together with rehabilitation specialists to jointly manage patient care. A team-based care model provides patients with all necessary medical services beginning with diagnosis and extending to treatment as well as rehabilitation and ongoing healthcare follow-ups. Healthcare improvements have solidified hospitals as the primary centres for specialized neurological care thus establishing them as essential institutions for managing these extensive medical issues. The global neurology market largely depends on hospitals because of specialized treatment needs and advanced technology which will sustain their dominant position in serving both acute and chronic neurological needs.

• In order to transform clinical trials and outcomes measurement for diseases of the central nervous system (CNS), including neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, Medidata, a Dassault Systèmes brand and the top supplier of clinical trial solutions to the life sciences sector, announced a collaboration with Cogstate, a leader in neuroscience solutions. By working together, the businesses will provide a better experience, backed by Medidata eCOA (electronic clinical outcome assessment), which gives clients more authority by enabling quicker trial initiation and better rater experiences. This offers a full set of data quality assurance tools for central nervous system (CNS) assessments, as well as a simplified rater trip via a single mobile device app.

Some of the Key Market Players

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Johnson & Johnson
• Lundbeck A/S
• Medtronic plc
• Novartis AG
• Pfizer Inc.
• Roche Holding AG

Report Description

• Market Introduction
• Market Dynamics
• Segment Analysis
• Some of the Key Market Players